A Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia

This phase 2 randomized, double‐blind, placebo‐controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson's disease and levodopa‐induced dyskinesia.

[1]  W. Poewe,et al.  Mavoglurant in Parkinson's patients with l‐Dopa‐induced dyskinesias: Two randomized phase 2 studies , 2016, Movement disorders : official journal of the Movement Disorder Society.

[2]  D. Hoyer,et al.  AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation , 2015, British journal of pharmacology.

[3]  L. Grégoire,et al.  AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. , 2014, Parkinsonism & related disorders.

[4]  S. Preskorn,et al.  Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition: A Proof of Concept, Randomized Trial in Patients with Schizophrenia , 2014, Journal of psychiatric practice.

[5]  M. Bencherif,et al.  Nicotinic Receptor Agonists Reduce l-DOPA–Induced Dyskinesias in a Monkey Model of Parkinson's Disease , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[6]  J. Waring,et al.  Preclinical characterization of a selective alpha-7 neuronal nicotinic acetylcholine receptor agonist ABT-126: A novel therapeutic agent for the treatment of cognitive impairment in Alzheimer's disease and schizophrenia , 2013, Alzheimer's & Dementia.

[7]  F. Meneghello,et al.  Morphometric evidence of neuroplastic effects induced by intensive cognitive stimulation in healthy ageing and in mild cognitive impairment , 2013, Alzheimer's & Dementia.

[8]  J. Lieberman,et al.  A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia , 2013, Neuropsychopharmacology.

[9]  K. Takata,et al.  3‐[(2,4‐dimethoxy)benzylidene]‐anabaseine dihydrochloride protects against 6‐hydroxydopamine‐induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats , 2013, Journal of neuroscience research.

[10]  J. Nutt,et al.  Which dyskinesia scale best detects treatment response? , 2013, Movement disorders : official journal of the Movement Disorder Society.

[11]  Gary Maurice Dull,et al.  Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders. , 2012, Journal of medicinal chemistry.

[12]  R. Barker,et al.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines , 2012, Movement disorders : official journal of the Movement Disorder Society.

[13]  D. Bertrand,et al.  EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors , 2012, Neuropharmacology.

[14]  W. Poewe,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[15]  M. Quik,et al.  Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats , 2011, Neuropharmacology.

[16]  R. Papke,et al.  TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. , 2009, Biochemical pharmacology.

[17]  M. Quik,et al.  Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys , 2009, Journal of neurochemistry.

[18]  D. Hoyer,et al.  The selective nicotinic acetylcholine receptor α7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain , 2009, Neuropharmacology.

[19]  M. Quik,et al.  Continuous and Intermittent Nicotine Treatment Reduces l-3,4-Dihydroxyphenylalanine (l-DOPA)-Induced Dyskinesias in a Rat Model of Parkinson's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[20]  D. D. Di Monte,et al.  Nicotine reduces levodopa‐induced dyskinesias in lesioned monkeys , 2007, Annals of neurology.

[21]  C. Goetz,et al.  Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.

[22]  D. Hoyer,et al.  JN403, in vitro characterization of a novel nicotinic acetylcholine receptor α7 selective agonist , 2007, Neuroscience Letters.

[23]  P. Maruff,et al.  Practice Effects Associated with the Repeated Assessment of Cognitive Function Using the CogState Battery at 10-minute, One Week and One Month Test-retest Intervals , 2006, Journal of clinical and experimental neuropsychology.

[24]  M. O'Neill,et al.  Nicotine, but neither the α4β2 ligand RJR2403 nor an α7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle , 2006, Neuropharmacology.

[25]  J. Langston,et al.  Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates , 2006, Journal of neurochemistry.

[26]  Robert Freedman,et al.  Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia , 2006 .

[27]  J. Langston,et al.  Chronic Oral Nicotine Normalizes Dopaminergic Function and Synaptic Plasticity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Primates , 2006, The Journal of Neuroscience.

[28]  M. Hajós,et al.  The Selective α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide Hydrochloride] Enhances GABAergic Synaptic Activity in Brain Slices and Restores Auditory Gating Deficits in Anesthetized Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.

[29]  Laurent Gerbaud,et al.  Impact of the motor complications of Parkinson's disease on the quality of life , 2005, Movement disorders : official journal of the Movement Disorder Society.

[30]  A. Burnett,et al.  Safety, Pharmacokinetics, and Effects on Cognitive Function of Multiple Doses of GTS-21 in Healthy, Male Volunteers* , 2003, Neuropsychopharmacology.

[31]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[32]  J. Drago,et al.  Dose‐related neuroprotective effects of chronic nicotine in 6‐hydroxydopamine treated rats, and loss of neuroprotection in α4 nicotinic receptor subunit knockout mice , 2001, British journal of pharmacology.

[33]  E. Hirsch,et al.  Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice , 2001, Brain Research.

[34]  W. J. Goodwin.  US Department of Health, Education and Welfare, National Institutes of Health: Regional Primate Research Centers. The Creation of a Program. Bethesda, Md. 1968. 67 pp., 2 tables. Obtainable at no cost. , 1972, Journal of Medical Primatology.

[35]  W. Oertel,et al.  The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice. , 2013, Journal of Parkinson's disease.

[36]  鈴木 秀一郎.  3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats , 2013 .

[37]  M. O'Neill,et al.  Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. , 2006, Neuropharmacology.

[38]  R. Freedman,et al.  Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. , 2006, Archives of general psychiatry.

[39]  N. Higdon,et al.  The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. , 2005, The Journal of pharmacology and experimental therapeutics.

[40]  Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. , 2001, Archives of neurology.

[41]  R. Papke,et al.  Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes. , 1995, Molecular pharmacology.

[42]  Y. Agid,et al.  Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology , 1994, Movement disorders : official journal of the Movement Disorder Society.

[43]  F. Goodwin.  From the Alcohol, Drug Abuse, and Mental Health Administration. , 1991, JAMA.

[44]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[45]  Diane C. Tsai.  Recent Developments in Parkinson's Disease , 1986, The Yale Journal of Biology and Medicine.

[46]  R. Hurst,et al.  The Selective Α 7 Nicotinic Acetylcholine Receptor Agonist Pnu-282987 Enhances Gabaergic Synaptic Activity in Brain Slices and Restores Auditory Gating Deficits in Anesthetized Rats , 2022 .